10-Q · May 14, 2026
CNS Pharmaceuticals reported a net loss of approximately $4.937 million for Q1 2026, which is larger than the $4.301 million loss in Q1 2025, indicating worsening financial performance. The company continues to face…
Earnings analysis · 10-Q
CNSP earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
CNS Pharmaceuticals remained a pre-revenue biotechnology company, with no revenue, EPS, segment revenue, or margin data disclosed in the provided filing text. Second-quarter operating expenses increased 12.1% year over…
Read full summary
CNS Pharmaceuticals remained a pre-revenue biotechnology company, with no revenue, EPS, segment revenue, or margin data disclosed in the provided filing text. Second-quarter operating expenses increased 12.1% year over year to $2.700 million and net loss increased 9.0% to $2.588 million, while six-month operating cash burn was $8.2 million. The $22.5 million private placement increased cash to approximately $20.0 million and supports operations beyond 12 months, but management expects to need significant additional capital and disclosed ineffective controls as of June 30, 2026.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Operating Loss Widened 12.1%
Second-quarter operating expenses rose 12.1% year over year to $2.700 million from $2.409 million, producing a $2.700 million operating loss versus $2.409 million. Net loss increased 9.0% to $2.588 million from $2.375 million.
-
G&A Spending Increased
General and administrative expense increased 20.7% year over year to $1.499 million from $1.242 million, primarily due to a $0.6 million increase in headcount-related expenses, partly offset by a $0.3 million reduction in professional services.
-
Operating Cash Burn Moderated
Six-month operating cash outflow improved modestly to $8.2 million from $8.6 million in the prior-year period. Investing cash use was de minimis in both periods, indicating limited reported capital-spending intensity.
-
$22.5M Financing Extended Runway
Cash was approximately $20.0 million and the working-capital surplus was approximately $18.2 million at June 30, 2026. The May 2026 private placement generated gross proceeds of approximately $22.5 million, and management said combined resources should fund planned operations beyond 12 months.
-
Financing Supported Liquidity
Six-month net cash provided by financing activities was approximately $21.0 million versus $14.3 million in the prior-year period, including proceeds from the May offering partly offset by note repayments.
-
Strategy Pivot and Trial Close-Out
The company is pivoting from a singular focus on glioblastoma multiforme toward broader serious-disease therapies and exploring out-licensing for TPI 287 and Berubicin. Berubicin enrollment and patient treatment are complete, with R&D expense still including trial close-out activity.
What to watch
-
Continued Losses and Cash Burn
The company reported a six-month net loss of $7.525 million and used $8.2 million in operating cash. Management stated that significant additional capital will be needed and that failure to raise funds could require reducing overhead, scaling back the business plan, or ceasing operations entirely.
-
Potential Financing Dilution
The May 5, 2026 financing included 650,000 common shares and pre-funded warrants for 9,143,479 shares, creating substantial potential dilution. Management also said it has no commitments for the additional financing needed to advance future drug candidates.
-
Material Internal-Control Weakness
Disclosure controls remained ineffective as of June 30, 2026 because of material weaknesses involving lack of segregation of duties, incomplete and untimely CRO cost information, and insufficient formal control documentation. Management stated that actions to improve documentation will not address the segregation-of-duties weakness.
Management's outlook
No numeric revenue or EPS guidance was provided. Management stated that cash resources are sufficient to fund planned operations beyond 12 months from the date the financial statements were issued, but also said significant additional capital will be required to execute the business plan.
Earlier filings 4
10-K · April 30, 2026
CNS Pharmaceuticals has undergone a strategic pivot towards broader neurology and oncology M&A activities, alongside a complete overhaul of its executive team in early 2026. Despite incremental improvements in diluted…
10-K · March 31, 2026
CNS Pharmaceuticals executed a strategic pivot in March 2026 from a single-focus GBM strategy to a broader neurology and oncology asset acquisition/in‑licensing strategy and rebuilt its executive team (CEO appointed Jan…
10-Q · November 14, 2025
CNS Pharmaceuticals reported no revenue for the quarter and a net loss of $3,218,481 for the three months ended September 30, 2025 (quarterly EPS of $(5.76)), an improvement versus the prior-year quarter net loss of…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.